<DOC>
	<DOCNO>NCT00453479</DOCNO>
	<brief_summary>GSK233705 high-affinity specific muscarinic receptor ( mAChR ) antagonist develop treatment chronic obstructive pulmonary disease . This randomised , double-blind , placebo-controlled , dose ascending , parallel group study examine safety , tolerability , pharmacokinetics pharmacodynamics twice daily inhaled dos GSK233705B 7 day , COPD subject .</brief_summary>
	<brief_title>A Dose Ascending , Study To Examine The Safety , Tolerability , Pharmacokinetics And Pharmacodynamics Of GSK233705B .</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Men woman 40 75 year age Female subject must nonchildbearing Subject diagnose COPD Body Mass Index 18.0 32.0 kg/m2 ( inclusive ) Subject smoker exsmoker Subject postbronchodilator ( 200µg salbutamol ) FEV1 = 40 % = 80 % predict normal . Subject FEV1/FVC &lt; 0.7 postbronchodilator ( 200µg salbutamol ) . Capable give write informed consent , include compliance requirement restriction list consent form . Subject available complete study measurement procedure . Subjects 24hour holter record within normal limit demonstrate clinically important abnormality , opinion investigator , would make subject unsuitable participation study . Subjects past present disease , judge Investigator Medical Monitor , may affect outcome study . The subject positive prestudy alcohol screen . The subject positive prestudy drug screen . History alcohol/drug abuse dependence within 12 month study : Abuse The subject positive pregnancy test . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Subject test positive HIV The subject participate clinical trial receive drug new chemical entity within 60 day 5 halflives Exposure three new chemical entity ( NCE ) within 10 month prior first dose day one NCE within 3 month prior first dose day . The subject donate unit ( 400ml ) blood within 60 day screening , , intend donate study . The subject know allergy hypersensitivity ipratropium bromide , atropine derivative milk protein/lactose . History sensitivity study medication , component thereof history drug allergy , opinion physician responsible , contraindicate participation Subject prostate hypertrophy narrow angle glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Chronic obstructive pulmonary disease ,</keyword>
	<keyword>muscarinic receptor ,</keyword>
	<keyword>bronchodilator</keyword>
</DOC>